Swiss biotech company Serono and Denmark's Genmab enter agreement  

Switzerland's Serono has gained global exclusive rights to develop and commercialise Copenhagen based Genmab's HuMax-CD4 for initial payment of a licence fee and equity investment totalling USD 70 mn

Swiss biotech company Serono and Copenhagen based Genmab have entered an agreement under which Genmab grants Serono worldwide exclusive rights to develop and commercialise Genmab's antibody product HuMax-CD4 for the treatment of skin cancer. Genmab will receive a licence fee of USD 20 mn (DKK 121 mn), and Serono will also make a USD 50 mn (DKK 303 mn) investment in Genmab common stock making the Swiss biotech company into the second largest shareholder of Genmab with a 7.6% stake.

HuMax-CD4 is currently being evaluated in a pivotal Phase III clinical trial for cutaneous T-cell lymphoma, and has a fast track designation from FDA. HuMax-CD4 is also being studied in a Phase II trial for non-cutaneous T-cell lymphoma. The news was reported by financial daily newspaper Børsen and on Genmab's website.

Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases such as cancer and rheumatoid arthritis. Genmab has partnership agreements with companies such as Roche and Amgen. In addition to Genmab's activities in Denmark, it has operations in Utrecht, Holland and Princeton, New Jersey in the US.

Link > Genmab 

Link > Serono 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×